Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...
For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.
AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037
With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...
Investor's Business Daily on MSN
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
AbbVie leaned hard on Skyrizi, Rinvoq and Botox to offset continued steep declines from Humira, an analyst said Friday as ...
Discover AbbVie's Q3 2025 earnings: strong EPS, raised guidance, robust pipeline, and growth drivers like Skyrizi and Rinvoq.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback